静脉短效β2受体激动剂联合一线治疗儿童急性重症哮喘发作的系统评价与荟萃分析
该研究纳入4项随机对照试验共183例儿童及青少年急性重症哮喘发作患者,比较静脉短效β2受体激动剂(SABA)与安慰剂联合标准一线治疗的效果。结果显示静脉SABA组哮喘严重度评分更优、住院时间更短、氧疗时间更少,机械通气需求和静脉治疗升级需求相似,不良事件包括心动过速、低血压和低钾血症。证据确定性为低至中等。
要点
- 静脉SABA可改善急性重症哮喘严重度评分(RR=0.38,95%CI 0.19–0.78,p=0.009)。
- 静脉SABA缩短住院时间(MD=-18.68小时,95%CI -36.76至-0.61)和氧疗时间(MD=-1.73天,95%CI -3.01至-0.45,p=0.008)。
- 机械通气需求与静脉治疗升级需求无显著差异,不良事件包括心动过速、低血压和低钾血症。
核心结论
- 低至中等确定性证据提示静脉SABA可改善儿童急性重症哮喘发作的严重度,不良事件不常见。
- 证据受纳入研究数量有限所限。
研究设计与样本
- 系统评价与荟萃分析,仅纳入随机对照试验(RCT),共4项RCT、183例参与者。
- 检索MEDLINE、Embase、Cochrane CENTRAL、Web of Science和CINAHL至2024年5月,遵循系统评价国际指南。
主要发现
- 静脉SABA组哮喘严重度评分优于对照组(RR=0.38,95%CI 0.19–0.78,p=0.009)。
- 机械通气需求相似(RR=0.13,95%CI 0.01–2.42,p=0.17)。
- 静脉治疗升级需求相似(RR=1.51,95%CI 0.60–3.82,p=0.38)。
- 住院时间更短(MD=-18.68小时,95%CI -36.76至-0.61)。
- 氧疗时间更少(MD=-1.73天,95%CI -3.01至-0.45,p=0.008)。
关键数值与推荐
- 不良事件包括心动过速、低血压和低钾血症。
- 一项研究报告静脉SABA组1例心律失常,肌钙蛋白I升高无统计学意义。
临床怎么用
- 在标准一线治疗基础上,静脉SABA可考虑用于儿童及青少年急性重症哮喘发作以改善严重度并缩短住院和氧疗时间。
- 使用时应监测心动过速、低血压、低钾血症及心律失常等不良事件。
局限性
- 纳入研究数量有限(仅4项RCT、183例参与者),证据确定性为低至中等。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The role of intravenous short-acting beta-2 agonist (SABA) in acute asthma in childhood is unclear. OBJECTIVES: To assess the safety and efficacy of intravenous SABA versus placebo for acute asthma. DATA SELECTION AND EXTRACTION: We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, the Web of Science and the Cumulative Index to Nursing and Allied Health Literature up to May 2024. We included only randomised controlled trials (RCTs) and followed the international guidelines for conducting systematic reviews. Outcomes measured were morbidity, escalation of care, length of hospital stay, adverse events, mortality and changes in lung functions. RESULTS: Four RCTs were included (total participants=183). Intravenous SABA group had better asthma severity scores (risk ratio (RR)=0.38, 95% CI 0.19 to 0.78, p=0.009), similar need for mechanical ventilation (RR=0.13, 95% CI 0.01 to 2.42, p=0.17), similar escalation of intravenous treatment (RR=1.51, 95% CI 0.60 to 3.82, p=0.38), shorter duration of hospital stay (hours) (mean difference (MD)=-18.68, 95% CI -36.76 to -0.61) and less duration of oxygen supplementation (days) (MD=-1.73, 95% CI -3.01 to -0.45, p=0.008). Adverse events were tachycardia, hypotension and hypokalaemia. One study reported a single participant with arrhythmia and a non-significant increase in troponin I among the intravenous SABA group. CONCLUSION: This review found low-to-moderate certainty evidence that intravenous SABA would improve acute asthma severity with infrequent adverse events reported. However, this evidence is limited due to the limited number of included studies. PROSPERO REGISTRATION NUMBER: CRD42023405119.
引用
- Abdelgadir IS, Hamud A, Mudawi K, et al. Use of intravenous short-acting beta-2 agonist in addition to standard first-line treatment versus placebo in children and adolescents with acute severe asthma exacerbation: a systematic review and meta-analysis. Arch Dis Child. 2025. PMID: 40562456. doi:10.1136/archdischild-2024-327452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。